Shares Of Avalanche Biotech Plummet After-Hours After Mediocre Results In Macular Degeneration Study
June 15, 2015 at 20:28 PM EDT
Shares of Avalanche Biotech are down 40% in after-hours trade today after reporting mediocre phase 2 results in Macular Degeneration. The stock dropped 6% during market hours.
